O Storrø1, T Øien, Ø Langsrud, K Rudi, C Dotterud, R Johnsen. 1. Department of Community Medicine and General Practice, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. ola.storro@ntnu.no
Abstract
BACKGROUND: Intestinal microbiota undergoes substantial development during the first 2 years of life, important for intestinal immunologic development and maturation influencing systemic immune responses. OBJECTIVE: We aimed to investigate, using a prospective study design, whether allergen-specific IgE (sIgE) and atopic eczema are associated with variations in gut microbial colonization patterns in an unselected population during the first 2 years of life. METHODS: Faeces from 94 infants were repeatedly sampled from 10 days, 4 months, 1 and 2 years postnatal and analysed for 12 different bacterial species by quantitative real-time PCR. Venous blood samples from the infants were collected at 2 years of age and were analysed for sIgE for 12 specific allergens. The temporal gut colonization patterns for 42 sIgE-positive (sIgE≥0.35 kU/L) and 52 sIgE-negative children (sIgE<0.1 kU/L) were then compared. The association between colonization pattern and phenotype as atopic eczema according to UK Working Party (UKWP) criteria were also described. RESULTS: Subjects with atopic sensitization had lower levels of Escherichia coli at 4 months and 1 year, higher levels of Bifidobacterium longum at 1 year and lower levels of Bacteroides fragilis at 2 years. For E. coli and B. longum, the differences were only transient and had disappeared by 2 years of age. For other species, there were no differences in colonization patterns, and we found no association between colonization pattern and atopic eczema. CONCLUSIONS AND CLINICAL RELEVANCE: We found temporal and transient variations in gut microbial colonization patterns associated with differences in sIgE sensitization at 2 years of age. A full understanding of the principles and mechanisms that underlie intestinal microbial colonization and diversity and host-microbiota relationships will be pivotal for the development of therapeutic approaches that manipulate the intestinal microbiota to maintain human health. [ REGISTRATION NUMBER: ISRCTN28090297].
BACKGROUND: Intestinal microbiota undergoes substantial development during the first 2 years of life, important for intestinal immunologic development and maturation influencing systemic immune responses. OBJECTIVE: We aimed to investigate, using a prospective study design, whether allergen-specific IgE (sIgE) and atopic eczema are associated with variations in gut microbial colonization patterns in an unselected population during the first 2 years of life. METHODS: Faeces from 94 infants were repeatedly sampled from 10 days, 4 months, 1 and 2 years postnatal and analysed for 12 different bacterial species by quantitative real-time PCR. Venous blood samples from the infants were collected at 2 years of age and were analysed for sIgE for 12 specific allergens. The temporal gut colonization patterns for 42 sIgE-positive (sIgE≥0.35 kU/L) and 52 sIgE-negative children (sIgE<0.1 kU/L) were then compared. The association between colonization pattern and phenotype as atopic eczema according to UK Working Party (UKWP) criteria were also described. RESULTS: Subjects with atopic sensitization had lower levels of Escherichia coli at 4 months and 1 year, higher levels of Bifidobacterium longum at 1 year and lower levels of Bacteroides fragilis at 2 years. For E. coli and B. longum, the differences were only transient and had disappeared by 2 years of age. For other species, there were no differences in colonization patterns, and we found no association between colonization pattern and atopic eczema. CONCLUSIONS AND CLINICAL RELEVANCE: We found temporal and transient variations in gut microbial colonization patterns associated with differences in sIgE sensitization at 2 years of age. A full understanding of the principles and mechanisms that underlie intestinal microbial colonization and diversity and host-microbiota relationships will be pivotal for the development of therapeutic approaches that manipulate the intestinal microbiota to maintain human health. [ REGISTRATION NUMBER: ISRCTN28090297].
Authors: Carmen W H Chan; Rosa S Wong; Patrick T W Law; Cho Lee Wong; Stephen K W Tsui; Winnie P Y Tang; Janet W H Sit Journal: Int J Mol Sci Date: 2016-07-16 Impact factor: 5.923
Authors: Eric J de Muinck; Karin Lagesen; Jan Egil Afset; Xavier Didelot; Kjersti S Rønningen; Knut Rudi; Nils Chr Stenseth; Pål Trosvik Journal: BMC Genomics Date: 2013-02-05 Impact factor: 3.969
Authors: Eric J de Muinck; Nils Chr Stenseth; Daniel Sachse; Jan Vander Roost; Kjersti S Rønningen; Knut Rudi; Pål Trosvik Journal: PLoS One Date: 2013-06-14 Impact factor: 3.240
Authors: Lotta Nylund; Reetta Satokari; Janne Nikkilä; Mirjana Rajilić-Stojanović; Marko Kalliomäki; Erika Isolauri; Seppo Salminen; Willem M de Vos Journal: BMC Microbiol Date: 2013-01-23 Impact factor: 3.605